TY - JOUR
T1 - The tight junction in inflammatory disease
T2 - communication breakdown
AU - Edelblum, Karen L.
AU - Turner, Jerrold R.
N1 - Funding Information:
The authors are supported by the National Institutes of Health T32HL007237 and F32DK084859 (KLE), R01DK061931 and R01DK068271 (JRT), and the Crohn's and Colitis Foundation of America (JRT).
PY - 2009/12
Y1 - 2009/12
N2 - The intestinal epithelium restricts free passage of toxic and infectious molecules from the gut lumen while allowing selective paracellular absorption across the tight junction. Inflammatory bowel disease (IBD) patients demonstrate a loss of tight junction barrier function, increased pro-inflammatory cytokine production, and immune dysregulation; however, the relationship between these events is incompletely understood. Although tight junction barrier defects are insufficient to cause experimental IBD, mucosal immune activation is altered in response to increased epithelial permeability. Thus, an evolving model suggests that barrier dysfunction may predispose or enhance disease progression and therapies targeted to specifically restore the barrier function may provide an alternative or supplement to immunology-based therapies.
AB - The intestinal epithelium restricts free passage of toxic and infectious molecules from the gut lumen while allowing selective paracellular absorption across the tight junction. Inflammatory bowel disease (IBD) patients demonstrate a loss of tight junction barrier function, increased pro-inflammatory cytokine production, and immune dysregulation; however, the relationship between these events is incompletely understood. Although tight junction barrier defects are insufficient to cause experimental IBD, mucosal immune activation is altered in response to increased epithelial permeability. Thus, an evolving model suggests that barrier dysfunction may predispose or enhance disease progression and therapies targeted to specifically restore the barrier function may provide an alternative or supplement to immunology-based therapies.
UR - http://www.scopus.com/inward/record.url?scp=70449466824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449466824&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2009.06.022
DO - 10.1016/j.coph.2009.06.022
M3 - Review article
C2 - 19632896
AN - SCOPUS:70449466824
VL - 9
SP - 715
EP - 720
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
IS - 6
ER -